BioSpace News Archive

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, reports its cash position as of 30 September 2020.

The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to February 28, 2021

NeoDynamics AB, a MedTech company dedicated to advancing diagnosis and care of breast cancer, announces that the Company has received the first UK order from the Buckinghamshire Healthcare NHS Trust, London, of its pulse biopsy system, NeoNavia.

There were no sales during the period. Revenue amounted to SEK 2.643 m (4.581 m) including capitalized costs of SEK 2.051 m (4.469 m).

SIFI, a leading ophthalmic company, announced that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis in its pivotal Phase III clinical trial.

NanoViricides, Inc., a leader in developing novel nanomedicines to treat viral diseases, announced that Mr. Brian Zucker, CPA, has joined the Company’s Board of Directors, effective November 13, 2020, as an independent director.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS).

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced new clinical results from its Phase 1 study evaluating rivoceranib (apatinib)

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. Monica Bertagnolli to its board of directors.

endpoint Clinical and McCreadie Group have collaborated to increase study product accountability transparency for study sponsors, reduce site burdens associated with clinical study IMP management, and improve related data integrity via carefully balanced interfacing of McCreadie’s site-based Vestigo® application and endpoint’s PULSE® IRT.